CTMX · XBRL financial data

CytomX Therapeutics financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CTMX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	100,362	37,312	53,163	101,214	138,103	76,201
Revenue from contracts with customers	100,362	37,312	53,163	101,214	138,103	76,201
Research and development	112,936	114,194	111,649	77,680	83,382	68,728
General and administrative	36,031	39,160	42,849	30,018	29,726	29,837
Total operating expenses	148,967	153,354	154,498	107,698	113,108	98,565
Operating income (loss)	(48,605)	(116,042)	(101,335)	(6,484)	24,995	(22,364)
Interest income	1,836	255	1,678	9,837	7,136	5,206
Other income (expense)	(27)	(83)	340	(30)	(38)	28
Income tax expense (benefit)	(13,911)	0	0	3,892	224	238
Net income (loss)	(32,885)	(115,870)	(99,317)	(569)	31,869	(17,368)
Weighted average shares, basic thousands of shares	46,146	64,147	65,740	73,808	84,439	137,936
Weighted average shares, diluted thousands of shares	46,146	64,147	65,740	73,808	84,745	137,936

Fiscal years (CTMX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	191,859	205,530	193,650	17,171	38,052	12,667
Marketable securities	124,260	99,696	0	157,338	62,571	124,385
Accounts receivable	798	790	35,986	3,432	3,103	2,013
Prepaid and other current assets	7,096	4,285	7,466	4,995	3,579	4,856
Total current assets	324,013	310,301	237,102	182,936	107,305	143,921
Property and equipment, net	6,950	5,960	5,072	3,958	2,467	1,304
Right-of-use asset	22,495	19,362	15,949	12,220	8,136	3,396
Goodwill	949	949	949	949	949	949
Total assets	358,663	339,411	260,891	201,792	120,533	151,566
Accounts payable	2,996	2,818	2,809	1,458	1,088	1,301
Accrued liabilities	23,059	34,236	28,532	17,599	12,338	14,197
Total current liabilities	100,924	77,870	152,608	155,913	85,772	46,615
Lease liability, non-current	21,675	18,056	13,975	9,385	4,240	0
Total liabilities	308,860	339,870	346,642	249,239	120,989	52,558
Accumulated deficit	(450,115)	(623,562)	(722,879)	(723,448)	(691,579)	(711,949)
Total stockholders' equity	49,803	(459)	(85,751)	(47,447)	(456)	99,008
Total liabilities and equity	358,663	339,411	260,891	201,792	120,533	151,566
Common shares outstanding (cover page) thousands of shares	64,784	65,393	66,228	67,722	80,100	170,187

Fiscal years (CTMX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(32,885)	(115,870)	(99,317)	(569)	31,869	(17,368)
Stock-based compensation	14,786	13,167	13,125	8,558	7,668	6,302
Net cash from operating activities	5,259	(119,031)	(110,788)	(56,035)	(86,231)	(75,587)
Purchases of property and equipment	2,309	1,609	1,740	840	310	220
Net cash from investing activities	(18,718)	22,489	98,260	(150,674)	99,700	(59,744)
Proceeds from issuing common stock	11,288	107,712	0	—	6,909	109,635
Net cash from financing activities	16,893	110,213	648	30,230	7,522	110,446

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
CytomX Therapeutics	17,224	1,418	(18,068)*	217.9M	18.3 quarters	Q2 FY26 10-QJun 30, 2026
Oruka Therapeutics	268,470	not reported	(33,145)*	66.2M	26.4 quarters	Q2 FY26 10-QJun 30, 2026
Cronos Group	467,019	53,007	24,010*	368.4M	—	Q2 FY26 10-QJun 30, 2026
REGENXBIO	36,487	108,019	(62,238)*	66.0M	1.7 quarters	Q2 FY26 10-QJun 30, 2026
Capricor Therapeutics	20,935	not reported	(31,485)*	58.1M	7.6 quarters	Q2 FY26 10-QJun 30, 2026
Cryoport	269,267	48,971	1,131*	50.6M	—	Q2 FY26 10-QJun 30, 2026
Emergent BioSolutions	175,700	110,000	100,100*	51.4M	—	Q3 FY26 10-QSep 30, 2026
Northwest Biotherapeutics	595	807	(7,169)*	1.7B	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Amarin	156,512	39,550	9,223*	not reported	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.